ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2025

Abstract Number: 0837

Risk of New Proteinuria in Next Ten Years in SLE

Michelle Petri1, Ilayda Demirayak2, Andrea Fava3, Daniel Goldman1 and Laurence Magder4, 1Johns Hopkins University School of Medicine, Timonium, MD, 2Istanbul University, Istanbul, Turkey, 3Johns Hopkins University, Baltimore, MD, 4University of Maryland, Baltimore, Baltimore, MD

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2025

Keywords: Diagnostic criteria, Lupus nephritis, Systemic lupus erythematosus (SLE)

Session Information

Date: Sunday, October 26, 2025

Title: Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes I: Advances in Nephritis (0837–0842)

Session Type: Abstract Session

Session Time: 3:00PM-3:15PM

Background/Purpose: The current 2024 ACR Lupus Nephritis guidelines recommend checking the urine protein to creatinine ratio (UPCR) every 6-12 months. Early recognition of lupus nephritis (LN), though, would lead to earlier introduction of treatment and better outcomes. A risk formula to project a patient’s risk of incident proteinuria within 10 years of SLE diagnosis would allow more frequent UPCR checks in the highest risk population.

Methods: The analysis is based on 1,418 members of the Hopkins Lupus Cohort who had been followed for longer than one year since SLE diagnosis. Subjects who developed proteinuria before or in the year of SLE diagnosis were excluded. A multivariate equation to predict the risk of incident proteinuria was developed using a forward-stepwise approach, considering each of the univariate associates in turn, and adding the variable that led to the greatest reduction in Akaike’s Information Criterion (AIC).

Results: Univariate associates of incident (new) proteinuria after 1 year from SLE diagnosis are shown in Table 1. Table 2 shows the multivariate predictors of incident proteinuria. Major risk factors included non-Caucasian race and anti-Sm. Moderate risk factors included male sex, anti-RNP, anti-dsDNA, and low C4 at the time of SLE diagnosis. Based on this model we estimated the 10-year risk as a function of the number of risk factors a patient has (Table 3). A person with no risk factors has only a 2.6% chance of developing proteinuria in 10 years, whereas a person with all 8 risk factors has a 49% chance.

Conclusion: We built a risk score for proteinuria in the next 10 years that would allow clinicians to identify a high risk subset of SLE patients to target for more frequent measurement of urine protein to creatinine AND to consider earlier renal biopsy at even low levels of proteinuria. The risk factors include well accepted demographic variables (non-Caucasian race, male sex) and serologic tests that are easily available (low C4, anti-Sm, anti-RNP and anti-dsDNA).

Supporting image 1Table 1. Association between various manifestations in the first year after SLE diagnosis and eventual incidence proteinuria

Supporting image 2Table 2. Multivariable model to predict incident proteinuria

Supporting image 3Table 3. Risk of incident proteinuria within 10 years of SLE diagnosis as a function of the number of risk factors (Each row in Table 2 counts as 1 risk factor except Anti-Sm and “Other” race which count as 2 risk factors)


Disclosures: M. Petri: Amgen, 2, AnaptysBio, 2, Annexon Bio, 2, AstraZeneca, 2, 5, Atara Biosciences, 2, Aurinia, 2, 5, Autolus, 2, Bain Capital, 2, Baobab Therapeutics, 2, Biocryst, 2, Biogen, 2, Boxer Capital, 2, Cabaletto Bio, 2, Caribou Biosciences, 2, CTI Clinical Trial and Consulting Services, 2, CVS Health, 2, Dualitybio, 2, Eli Lilly, 2, 5, EMD Serono, 2, Emergent, 2, Escient Pharmaceuticals, 2, Exagen, 5, Exo Therapeutics, 2, Gentibio, 2, GlaxoSmithKlein(GSK), 2, 5, iCell Gene Therapeutics, 2, Innovaderm Research, 2, IQVIA, 2, Janssen, 5, Kezar Life Sciences, 2, Kira Pharmaceuticals, 2, Nexstone Immunology, 2, Nimbus Lakshmi, 2, Novartis, 2, Ono Pharma, 2, PPD Development, 2, Proviant, 2, Regeneron, 2, Seismic Therapeutic, 2, Senti Biosciences, 2, Sinomab Biosciences, 2, Steritas, 2, Takeda, 2, Tenet Medicines, 2, TG Therapeutics, 2, UCB, 2, Variant Bio, 2, Worldwide Clinical Trials, 2, Zydus, 2; I. Demirayak: None; A. Fava: Artiva, 2, AstraZeneca, 1, 2, Bain Capital, 2, Biogen, 1, Bristol-Myers Squibb(BMS), 2, Exagen, 5, 9, Quotient Therapeutics, 2, UCB, 6, Zenas, 2; D. Goldman: None; L. Magder: None.

To cite this abstract in AMA style:

Petri M, Demirayak I, Fava A, Goldman D, Magder L. Risk of New Proteinuria in Next Ten Years in SLE [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/risk-of-new-proteinuria-in-next-ten-years-in-sle/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-new-proteinuria-in-next-ten-years-in-sle/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology